The pluripotency factor NANOG controls primitive hematopoiesis and directly regulates Tal1
-
1.
The Francis Crick Institute
-
2.
Instituto de Salud Carlos III
-
3.
European Molecular Biology Laboratory
-
4.
Spanish National Centre for Cardiovascular Research
- 5. Centro Nacional de Microbiologia_ISCIII
-
6.
Centro Andaluz de Biología del Desarrollo
-
7.
Centro de Biología Molecular Severo Ochoa
-
8.
Dow University of Health Sciences
-
9.
Hospital Universitario 12 De Octubre
- 10. University of Florida
-
11.
University of Cambridge
-
12.
Altos Labs
Description
Progenitors of the first hematopoietic cells in the mouse arise in the early embryo from Brachyury-positive multipotent cells in the posterior-proximal region of the epiblast, but the mechanisms that specify primitive blood cells are still largely unknown. Pluripotency factors maintain uncommitted cells of the blastocyst and embryonic stem cells in the pluripotent state. However, little is known about the role played by these factors during later development, despite being expressed in the postimplantation epiblast. Using a dual transgene system for controlled expression at postimplantation stages, we found that Nanog blocks primitive hematopoiesis in the gastrulating embryo, resulting in a loss of red blood cells and downregulation of erythropoietic genes. Accordingly, Nanog-deficient embryonic stem cells are prone to erythropoietic differentiation. Moreover, Nanog expression in adults prevents the maturation of erythroid cells. By analysis of previous data for NANOG binding during stem cell differentiation and CRISPR/Cas9 genome editing, we found that Tal1 is a direct NANOG target. Our results show that Nanog regulates primitive hematopoiesis by directly repressing critical erythroid lineage specifiers.